BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1451 related articles for article (PubMed ID: 23448451)

  • 21. The kidney in Fabry's disease.
    Pisani A; Visciano B; Imbriaco M; Di Nuzzi A; Mancini A; Marchetiello C; Riccio E
    Clin Genet; 2014 Oct; 86(4):301-9. PubMed ID: 24645664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fabry disease.
    Germain DP
    Orphanet J Rare Dis; 2010 Nov; 5():30. PubMed ID: 21092187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anderson-Fabry disease: developments in diagnosis and treatment.
    Kes VB; Cesarik M; Zavoreo I; Madzar Z; Demarin V
    Acta Clin Croat; 2012 Sep; 51(3):411-7. PubMed ID: 23330407
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic renal failure, dialysis, and renal transplantation in Anderson-Fabry disease.
    Sessa A; Meroni M; Battini G; Righetti M; Mignani R
    Semin Nephrol; 2004 Sep; 24(5):532-6. PubMed ID: 15490423
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The neurological manifestations of Fabry disease. A review].
    Firsov KV; Kotov AS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(9):98-105. PubMed ID: 27735906
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phenotype and biochemical heterogeneity in late onset Fabry disease defined by N215S mutation.
    Lavalle L; Thomas AS; Beaton B; Ebrahim H; Reed M; Ramaswami U; Elliott P; Mehta AB; Hughes DA
    PLoS One; 2018; 13(4):e0193550. PubMed ID: 29621274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiac manifestations of Anderson-Fabry disease in heterozygous females.
    Kampmann C; Baehner F; Whybra C; Martin C; Wiethoff CM; Ries M; Gal A; Beck M
    J Am Coll Cardiol; 2002 Nov; 40(9):1668-74. PubMed ID: 12427421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Novel Missense GLA Mutation (p.G35V) Detected in Hemodialysis Screening Leads to Severe Systemic Manifestations of Fabry Disease in Men and Women.
    Veloso VSP; Ataides TL; Canziani MEF; Veloso MP; da Silva NA; Barreto DV; Pereira ERS; de Moura LAR; Barreto FC
    Nephron; 2018; 138(2):147-156. PubMed ID: 28892806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ultrastructural study of renal involvement in two females with Anderson-Fabry disease.
    Tosoni A; Nebuloni M; Zerbi P; Vago L; Comotti C; Sessa A
    Ultrastruct Pathol; 2005; 29(3-4):203-7. PubMed ID: 16036875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fabry disease and cardiovascular involvement.
    Anastasakis A; Papatheodorou E; Steriotis AK
    Curr Pharm Des; 2013; 19(33):5997-6008. PubMed ID: 23448453
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of fever/hyperthermia in the diagnosis of Fabry: A retrospective analysis.
    Verrecchia E; Zampetti A; Antuzzi D; Ricci R; Ferri L; Morrone A; Feliciani C; Dagna L; Manna R
    Eur J Intern Med; 2016 Jul; 32():26-30. PubMed ID: 27083555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vascular endothelial growth factor (VEGF-a) in Fabry disease: association with cutaneous and systemic manifestations with vascular involvement.
    Zampetti A; Gnarra M; Borsini W; Giurdanella F; Antuzzi D; Piras A; Smaldone C; Pieroni M; Cadeddu C; de Waure C; Feliciani C
    Cytokine; 2013 Mar; 61(3):933-9. PubMed ID: 23332617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cardiological follow-up in patients with Fabry disease].
    Pieruzzi F; Pieroni M; Chimenti C; Frustaci A; Sarais C; Cecchi F;
    G Ital Cardiol (Rome); 2010; 11(7-8):566-72. PubMed ID: 21033333
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fabry disease - Vascular manifestations.
    Karetova D; Bultas J; Dostalova G; Palecek T; Kovarnik T; Golan L; Linhart A
    Vasa; 2010 May; 39(2):123-31. PubMed ID: 20464667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiac Involvement in Fabry Disease and the Role of Multimodality Imaging in Diagnosis and Disease Monitoring.
    Umer M; Motwani M; Jefferies JL; Nagueh SF; Kalra DK
    Curr Probl Cardiol; 2023 Jan; 48(1):101439. PubMed ID: 36202174
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Neurological complications of Fabry-disease].
    Vastagh I; Constantin T; Kéri A; Rudas G; Fekete G; Bereczki D
    Ideggyogy Sz; 2011 Jan; 64(1-2):29-35. PubMed ID: 21428036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Ckd. Qld fabRy Epidemiology (aCQuiRE) study protocol: identifying the prevalence of Fabry disease amongst patients with kidney disease in Queensland, Australia.
    Mallett A; Kearey P; Cameron A; Healy H; Denaro C; Thomas M; Lee VW; Stark S; Fuller M; Hoy WE
    BMC Nephrol; 2020 Feb; 21(1):58. PubMed ID: 32087678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Case report: enzyme replacement therapy for Fabry disease presenting with proteinuria and ventricular septal thickening.
    Chen Z; Yin B; Jiao J; Ye T
    BMC Nephrol; 2024 Feb; 25(1):61. PubMed ID: 38383316
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fabry disease: A fundamental genetic modifier of cardiac function.
    Tadevosyan A
    Curr Res Transl Med; 2017; 65(1):10-14. PubMed ID: 28340691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiac manifestations in Fabry disease.
    Linhart A; Lubanda JC; Palecek T; Bultas J; Karetová D; Ledvinová J; Elleder M; Aschermann M
    J Inherit Metab Dis; 2001; 24 Suppl 2():75-83; discussion 65. PubMed ID: 11758683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 73.